Abstract: Based on specific experimental studies the invention relates to an optimized levonorgestrel-only-composition for improved continuous oral contraception with consequences for suitable pharmaceutical preparations for the same purpose and with defined levonorgestrel content. The invention relates to a pharmaceutical composition for oral contraception for a woman of fertile age consisting of 60 to 100 ?g of levonorgestrel and one or more pharmaceutical acceptable carriers and excipients. Furthermore, the invention relates to a pharmaceutical preparation for oral contraception consisting of a number of separately packed and individually removable daily dosage units intended for consecutive daily oral administration, each dosage unit consisting of 60 to 100 ?g of levonorgestrel and one or more pharmaceutical acceptable carriers and excipients. Additionally, the invention relates to a dosage regimen, i.e.